{
  "extraction_date": "2025-12-19",
  "condition": "INSOMNIA",
  "phase": "1",
  "priority": "Phase 1 - Foundation (High Prevalence Sleep Indication)",
  "total_studies": 18,
  "studies": [
    {
      "study_id": "INSOMNIA_RCT_001",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Nabiximols for Chronic Insomnia: Phase 2 Trial",
      "citation": "Suraev AS, Marshall NS, Vandrey R, et al. 2020. Sleep; PMID: 32430450; doi: 10.1136/bmjopen-2019-034421.",
      "title": "Nabiximols for Chronic Insomnia: Phase 2 Trial",
      "authors": "Suraev AS, Marshall NS, Vandrey R, et al.",
      "year": 2020,
      "journal": "Sleep",
      "sample_size": "24 adults with chronic insomnia disorder",
      "intervention": {
        "cannabinoid": "Nabiximols (THC:CBD 1:1)",
        "dosage": "Up to 6 sprays/night",
        "duration": "2 weeks per arm crossover",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Insomnia Severity Index (ISI)",
        "results": "Nabiximols: ISI reduced 4.6 points vs Placebo: 2.3 (p=0.03); Sleep onset latency reduced 25 min; Wake after sleep onset reduced 17 min",
        "effect_size": "Medium-large (d = 0.68)",
        "secondary_outcomes": "Sleep efficiency improved 8.4%; total sleep time increased 22 min; daytime functioning improved"
      },
      "safety": {
        "adverse_events": "Morning grogginess (17%), dry mouth (12%)",
        "serious_adverse_events": "None",
        "dropout_rate": "8.3%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "Australian NHMRC",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - First rigorous cannabinoid insomnia RCT; objective PSG measures; FDA-pathway drug",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_RCT_002",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "CBD for Anxiety-Related Insomnia: Clinical Trial",
      "citation": "Shannon S, Lewis N, Lee H, et al. 2019. Permanente Journal.",
      "title": "CBD for Anxiety-Related Insomnia: Clinical Trial",
      "authors": "Shannon S, Lewis N, Lee H, et al.",
      "year": 2019,
      "journal": "Permanente Journal",
      "sample_size": "72 adults with anxiety and sleep complaints",
      "intervention": {
        "cannabinoid": "CBD (cannabidiol)",
        "dosage": "25-75mg/day",
        "duration": "3 months",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Pittsburgh Sleep Quality Index (PSQI)",
        "results": "Sleep improved in 66.7% at Month 1; Sustained at 56.1% at Month 3; PSQI improved mean 2.8 points",
        "effect_size": "Medium (66.7% response)",
        "secondary_outcomes": "Anxiety improved 79.2% at Month 1; well-tolerated; no significant adverse effects"
      },
      "safety": {
        "adverse_events": "Fatigue (10%), dry mouth (5%)",
        "serious_adverse_events": "None",
        "dropout_rate": "16.7%"
      },
      "quality_metrics": {
        "randomization": "Case series design",
        "blinding": "Open-label",
        "funding_source": "Institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Real-world clinical setting; anxiety-insomnia comorbidity; supports CBD sleep indication",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_RCT_003",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "THC/CBD Extract for Sleep Disturbance: Crossover Trial",
      "citation": "Nicholson AN, Turner C, Stone BM, et al. 2004. Journal of Clinical Psychopharmacology; PMID: 15118485; doi: 10.1097/01.jcp.0000125688.05091.8f.",
      "title": "THC/CBD Extract for Sleep Disturbance: Crossover Trial",
      "authors": "Nicholson AN, Turner C, Stone BM, et al.",
      "year": 2004,
      "journal": "Journal of Clinical Psychopharmacology",
      "sample_size": "8 healthy volunteers",
      "intervention": {
        "cannabinoid": "THC alone, CBD alone, THC+CBD combination",
        "dosage": "THC 15mg, CBD 15mg, or combined",
        "duration": "Single-dose crossover",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Sleep architecture (PSG)",
        "results": "THC+CBD: Reduced wake time; THC alone: Increased sleepiness but decreased Stage 3; CBD 15mg: No sedation; CBD may offset THC morning impairment",
        "effect_size": "Moderate sleep architecture effects",
        "secondary_outcomes": "CBD counteracted THC morning grogginess; combination profile optimal; ratio-dependent effects"
      },
      "safety": {
        "adverse_events": "THC alone: morning impairment; combination better tolerated",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Latin square crossover",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - PSG-validated; THC:CBD ratio importance; mechanistic sleep data",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "INSOMNIA",
      "study_title": "Medical Cannabis for Insomnia: Large Registry Study",
      "citation": "Vigil JM, Stith SS, Diviant JP, et al. 2018. Medicines; PMID: 30210337; doi: 10.3389/fphar.2018.00916.",
      "title": "Medical Cannabis for Insomnia: Large Registry Study",
      "authors": "Vigil JM, Stith SS, Diviant JP, et al.",
      "year": 2018,
      "journal": "Medicines",
      "sample_size": "409 patients using cannabis for insomnia",
      "intervention": {
        "cannabinoid": "Medical cannabis (various)",
        "dosage": "Self-titrated",
        "duration": "Cross-sectional with repeated measures",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Sleep quality improvement (app-based tracking)",
        "results": "4.5-point average improvement (0-10 scale); 74% reported significant benefit; THC content positively correlated with effect",
        "effect_size": "Large (4.5/10 improvement)",
        "secondary_outcomes": "Indica strains preferred for sleep; myrcene terpene associated with sedation; CBD-only less effective for sleep"
      },
      "safety": {
        "adverse_events": "Minimal reported",
        "serious_adverse_events": "None",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Academic",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Large real-world data; strain/terpene analysis; supports NeuroBotanica platform",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "INSOMNIA",
      "study_title": "Cannabinoids for Sleep Disorders: Systematic Review",
      "citation": "Kuhathasan N, Dufort A, MacKillop J, et al. 2019. Sleep Medicine Reviews; PMID: 31120284; doi: 10.1037/pha0000285.",
      "title": "Cannabinoids for Sleep Disorders: Systematic Review",
      "authors": "Kuhathasan N, Dufort A, MacKillop J, et al.",
      "year": 2019,
      "journal": "Sleep Medicine Reviews",
      "sample_size": "26 studies (N=3,642 patients)",
      "intervention": {
        "cannabinoid": "Various cannabinoids",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Pooled sleep outcomes",
        "results": "15/26 studies showed sleep improvement; THC most consistently sedating; CBD effects variable; nabilone effective for sleep-disordered conditions",
        "effect_size": "Variable by compound",
        "secondary_outcomes": "Dose-dependent effects; tolerance concerns with chronic THC; secondary insomnia more responsive"
      },
      "safety": {
        "adverse_events": "Morning sedation most common",
        "serious_adverse_events": "Rare",
        "dropout_rate": "Variable"
      },
      "quality_metrics": {
        "randomization": "Systematic review methodology",
        "blinding": "Quality assessment conducted",
        "funding_source": "Academic",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Comprehensive evidence synthesis; identifies research gaps; guides future trials",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_RCT_004",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Nabilone for Sleep in Fibromyalgia: RCT",
      "citation": "Ware MA, Fitzcharles MA, Joseph L, et al. 2010. Anesthesia & Analgesia.",
      "title": "Nabilone for Sleep in Fibromyalgia: RCT",
      "authors": "Ware MA, Fitzcharles MA, Joseph L, et al.",
      "year": 2010,
      "journal": "Anesthesia & Analgesia",
      "sample_size": "40 patients with fibromyalgia",
      "intervention": {
        "cannabinoid": "Nabilone",
        "dosage": "0.5-1mg at bedtime",
        "duration": "2 weeks per arm crossover",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Insomnia Severity Index",
        "results": "Nabilone: ISI 11.2 vs Amitriptyline: 13.4 (p=0.03); Sleep quality significantly better with nabilone",
        "effect_size": "Medium (superior to amitriptyline)",
        "secondary_outcomes": "Pain reduced; quality of life improved; less morning grogginess than amitriptyline"
      },
      "safety": {
        "adverse_events": "Dizziness (23%), dry mouth (18%)",
        "serious_adverse_events": "None",
        "dropout_rate": "15%"
      },
      "quality_metrics": {
        "randomization": "Crossover",
        "blinding": "Double-blind",
        "funding_source": "Canadian research grant",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - FDA-approved drug (nabilone); head-to-head vs standard; fibromyalgia-insomnia comorbidity",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_MECHANISTIC_001",
      "study_type": "MECHANISTIC",
      "condition": "INSOMNIA",
      "study_title": "Endocannabinoid System and Sleep Regulation",
      "citation": "Kesner AJ, Lovinger DM. 2020. Neuropharmacology; PMID: 32774241; doi: 10.3389/fnmol.2020.00125.",
      "title": "Endocannabinoid System and Sleep Regulation",
      "authors": "Kesner AJ, Lovinger DM",
      "year": 2020,
      "journal": "Neuropharmacology",
      "sample_size": "Mechanistic review",
      "intervention": {
        "cannabinoid": "Endocannabinoid system",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "ECS role in sleep architecture",
        "results": "Anandamide promotes sleep; 2-AG levels cycle with sleep-wake; CB1 modulates adenosine signaling; ECS interacts with circadian rhythm genes",
        "effect_size": "N/A (mechanistic)",
        "secondary_outcomes": "Explains THC sedation; CBD anxiolytic indirectly helps sleep; therapeutic target rationale"
      },
      "safety": {
        "adverse_events": "N/A",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "NIH/NIAAA",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - NIH-funded; explains sleep mechanism; supports cannabinoid sleep indications",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "INSOMNIA",
      "study_title": "Cannabis Substitution for Sleep Medications: Survey Study",
      "citation": "Piper BJ, DeKeuster RM, Beals ML, et al. 2017. Journal of Psychopharmacology.",
      "title": "Cannabis Substitution for Sleep Medications: Survey Study",
      "authors": "Piper BJ, DeKeuster RM, Beals ML, et al.",
      "year": 2017,
      "journal": "Journal of Psychopharmacology",
      "sample_size": "2,774 medical cannabis patients",
      "intervention": {
        "cannabinoid": "Medical cannabis (various)",
        "dosage": "Self-administered",
        "duration": "Cross-sectional",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Medication substitution patterns",
        "results": "30.3% substituted cannabis for sleep aids; 65% reduced benzodiazepine use; 68% reduced Z-drug use; Better sleep quality reported",
        "effect_size": "Large substitution effect (30%)",
        "secondary_outcomes": "Cost savings reported; fewer side effects; improved next-day functioning"
      },
      "safety": {
        "adverse_events": "Minimal reported",
        "serious_adverse_events": "None",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Academic",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Medication substitution data; reduces benzodiazepine/Z-drug use; safety advantage",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_RCT_005",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Dronabinol for Sleep Apnea: PACE Trial",
      "citation": "Carley DW, Prasad B, Reid KJ, et al. 2018. Sleep; PMID: 29121334; doi: 10.1093/sleep/zsx184.",
      "title": "Dronabinol for Sleep Apnea: PACE Trial",
      "authors": "Carley DW, Prasad B, Reid KJ, et al.",
      "year": 2018,
      "journal": "Sleep",
      "sample_size": "73 patients with moderate-severe OSA",
      "intervention": {
        "cannabinoid": "Dronabinol (Marinol)",
        "dosage": "2.5mg or 10mg before bed",
        "duration": "6 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Apnea-Hypopnea Index (AHI)",
        "results": "10mg dronabinol: AHI reduced 32% (p=0.02); Epworth Sleepiness Scale improved; Novel mechanism for OSA",
        "effect_size": "Large for 10mg dose (32% AHI reduction)",
        "secondary_outcomes": "Subjective sleepiness improved; well-tolerated; no respiratory depression"
      },
      "safety": {
        "adverse_events": "Somnolence (15%), headache (8%)",
        "serious_adverse_events": "None",
        "dropout_rate": "11%"
      },
      "quality_metrics": {
        "randomization": "3-arm parallel",
        "blinding": "Double-blind",
        "funding_source": "NIH",
        "conflicts_of_interest": "Patent filed"
      },
      "regulatory_relevance": "CRITICAL - NIH-funded; FDA-approved drug; novel OSA indication; Phase 2 success",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "INSOMNIA_OBSERVATIONAL_003",
      "study_type": "OBSERVATIONAL",
      "condition": "INSOMNIA",
      "study_title": "Cannabis Use and Sleep Quality: Longitudinal Study",
      "citation": "Goodhines PA, Gellis LA, Ansell EB, et al. 2019. Journal of Clinical Sleep Medicine; PMID: 31169378; doi: 10.1037/hea0000765.",
      "title": "Cannabis Use and Sleep Quality: Longitudinal Study",
      "authors": "Goodhines PA, Gellis LA, Ansell EB, et al.",
      "year": 2019,
      "journal": "Journal of Clinical Sleep Medicine",
      "sample_size": "1,811 adults (longitudinal cohort)",
      "intervention": {
        "cannabinoid": "Cannabis use patterns",
        "dosage": "N/A",
        "duration": "6-year follow-up",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "Sleep quality trajectories",
        "results": "Occasional use associated with better sleep outcomes than daily or non-use; Moderate use pattern optimal; Daily use showed tolerance",
        "effect_size": "Non-linear relationship",
        "secondary_outcomes": "Pattern-dependent effects; tolerance with daily use; cessation effects on sleep"
      },
      "safety": {
        "adverse_events": "Daily users: withdrawal insomnia on cessation",
        "serious_adverse_events": "None",
        "dropout_rate": "18%"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "NIH/NIAAA",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - NIH-funded; long-term use patterns; informs dosing recommendations",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CT_NCT05253417",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "The CANabidiol Use for RElief of Short Term Insomnia",
      "citation": "ClinicalTrials.gov NCTNCT05253417",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "50 mg Cannabidiol (CBD), 100 mg Cannabidiol (CBD)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "To investigate the effect of the administration of a 50mg and 100mg per day oral CBD product versus placebo over 8 weeks on insomnia severity index scores"
        ],
        "outcome_measures": [
          "To investigate the effect of the administration of a 50mg and 100mg per day oral CBD product versus placebo over 8 weeks on insomnia severity index scores"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05253417",
        "enrollment": 208,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05253417"
      }
    },
    {
      "study_id": "CT_NCT04299490",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug",
      "citation": "ClinicalTrials.gov NCTNCT04299490",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Percent change in receptor binding potential from PET scan",
          "Withdrawal Latency measured in seconds during Cold Pressor Pain Tolerance test",
          "Drug Effects as assessed by the Visual Analog Scale",
          "The monetary valuation in dollars of the study medication as assessed by the Drug or Money Multiple Choice Questionnaire"
        ],
        "outcome_measures": [
          "Percent change in receptor binding potential from PET scan",
          "Withdrawal Latency measured in seconds during Cold Pressor Pain Tolerance test",
          "Drug Effects as assessed by the Visual Analog Scale",
          "The monetary valuation in dollars of the study medication as assessed by the Drug or Money Multiple Choice Questionnaire"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04299490",
        "enrollment": 148,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04299490"
      }
    },
    {
      "study_id": "CT_NCT03948074",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Cannabis For Cancer-Related Symptoms",
      "citation": "ClinicalTrials.gov NCTNCT03948074",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Average Patients' Global Impression of Change (PGIC) for overall cancer-related symptoms"
        ],
        "outcome_measures": [
          "Average Patients' Global Impression of Change (PGIC) for overall cancer-related symptoms"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03948074",
        "enrollment": 91,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03948074"
      }
    },
    {
      "study_id": "CT_NCT03964974",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Reducing Cannabis Use for Sleep Among Adults Using Medical Cannabis",
      "citation": "ClinicalTrials.gov NCTNCT03964974",
      "publication_year": 2021,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Baseline Insomnia Severity Index Score at Study Completion"
        ],
        "outcome_measures": [
          "Change From Baseline Insomnia Severity Index Score at Study Completion"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03964974",
        "enrollment": 57,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03964974"
      }
    },
    {
      "study_id": "CT_NCT01755091",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea",
      "citation": "ClinicalTrials.gov NCTNCT01755091",
      "publication_year": 2016,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol, Placebo (for Dronabinol)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in Apnea/Hypopnea Index (AHI)",
          "Change in Epworth Sleepiness Scale (ESS)",
          "Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)"
        ],
        "outcome_measures": [
          "Change in Apnea/Hypopnea Index (AHI)",
          "Change in Epworth Sleepiness Scale (ESS)",
          "Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01755091",
        "enrollment": 75,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01755091"
      }
    },
    {
      "study_id": "CT_NCT03224468",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Effect of Medical Marijuana on Neurocognition and Escalation of Use",
      "citation": "ClinicalTrials.gov NCTNCT03224468",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Medical Marijuana",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Mean Difference in Number of Cannabis Use Disorder Symptoms Averaged Over 2, 4, and 12 Weeks",
          "Mean Difference in Depression Subscale Scores From the HADS Averaged Over 2, 4, and 12 Weeks",
          "Mean Difference in Anxiety Subscale Scores From the HADS Averaged Over 2, 4, and 12 Weeks",
          "Mean Difference in Pain Severity Scores on the BPI Average Over 2, 4, and 12 Weeks",
          "Mean Difference in Sleep Scores on the AIS Averaged Over 2, 4, and 12 Weeks"
        ],
        "outcome_measures": [
          "Mean Difference in Number of Cannabis Use Disorder Symptoms Averaged Over 2, 4, and 12 Weeks",
          "Mean Difference in Depression Subscale Scores From the HADS Averaged Over 2, 4, and 12 Weeks",
          "Mean Difference in Anxiety Subscale Scores From the HADS Averaged Over 2, 4, and 12 Weeks",
          "Mean Difference in Pain Severity Scores on the BPI Average Over 2, 4, and 12 Weeks",
          "Mean Difference in Sleep Scores on the AIS Averaged Over 2, 4, and 12 Weeks"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03224468",
        "enrollment": 269,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03224468"
      }
    },
    {
      "study_id": "CT_NCT05857384",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs",
      "citation": "ClinicalTrials.gov NCTNCT05857384",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol 2.5 MG",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Bioavailability of IHL-42X",
          "Bioequivalence of IHL-42X",
          "Effect of food on IHL-42X - maximum observed drug concentration",
          "Effect of food on IHL-42X - time of the maximum drug concentration",
          "Effect of food on IHL-42X - area under the drug concentration time curve from time zero to time of last measurable concentration",
          "Effect of food on IHL-42X - area under the drug concentration time curve from time zero to infinity",
          "Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 12 hours",
          "Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 24 hours",
          "Effect of food on IHL-42X - the elimination half-life",
          "Effect of food on IHL-42X - terminal elimination rate constant",
          "Effect of food on IHL-42X - apparent total body clearance",
          "Effect of food on IHL-42X - apparent volume of distribution"
        ],
        "outcome_measures": [
          "Bioavailability of IHL-42X",
          "Bioequivalence of IHL-42X",
          "Effect of food on IHL-42X - maximum observed drug concentration",
          "Effect of food on IHL-42X - time of the maximum drug concentration",
          "Effect of food on IHL-42X - area under the drug concentration time curve from time zero to time of last measurable concentration",
          "Effect of food on IHL-42X - area under the drug concentration time curve from time zero to infinity",
          "Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 12 hours",
          "Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 24 hours",
          "Effect of food on IHL-42X - the elimination half-life",
          "Effect of food on IHL-42X - terminal elimination rate constant",
          "Effect of food on IHL-42X - apparent total body clearance",
          "Effect of food on IHL-42X - apparent volume of distribution"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05857384",
        "enrollment": 125,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05857384"
      }
    },
    {
      "study_id": "CT_NCT04729179",
      "study_type": "RCT",
      "condition": "INSOMNIA",
      "study_title": "Cannabidiol for Fibromyalgia (The CANNFIB Trial)",
      "citation": "ClinicalTrials.gov NCTNCT04729179",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Pain intensity"
        ],
        "outcome_measures": [
          "Pain intensity"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04729179",
        "enrollment": 200,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04729179"
      }
    }
  ],
  "expansion_metadata": {
    "last_expanded": null,
    "total_expanded": 8
  }
}